Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.62 |
| ▸ | CDK8 | P49336 | 3/20 | 0.55 |
| ▸ | BRAF | P15056 | 5/20 | 0.53 |
| ▸ | RAF1 | P04049 | 3/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5341654 | 0.93 | KDR (0.54) | KDRCDK8BRAFRAF1RET | |
| SCHEMBL5333931 | 0.92 | KDR (0.61) | KDRCDK8BRAFRAF1MAPK3 | |
| SCHEMBL5337325 | 0.88 | RET (0.63) | KDRCDK8BRAFRAF1RET | |
| SCHEMBL5419476 | 0.88 | KDR (0.54) | KDRBRAF | |
| SCHEMBL5341962 | 0.87 | KDR (0.63) | KDRCDK8BRAFRAF1RET | |
| SCHEMBL5434053 | 0.87 | KDR (0.62) | KDRCDK8BRAFRAF1RET | |
| SCHEMBL5442674 | 0.86 | KDR (0.64) | KDRCDK8BRAFRAF1RET | |
| SCHEMBL5402120 | 0.85 | KDR (0.64) | KDRCDK8BRAFRAF1RET | |
| SCHEMBL5419824 | 0.84 | KDR (0.57) | KDRCDK8BRAFRAF1RET | |
| SCHEMBL5426551 | 0.84 | KDR (0.63) | KDRCDK8BRAFRAF1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007076473-A2 | SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | KDR 555/4885CDK8 185/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.